Figure 1. A. Magnetic resonance imaging of the primary tumor at the baseline; B. progressive disease after two cycles of Temozolomide therapy.
Figure 2. A heterogenous contrast-enhancing lesion at the postcontrast axial T1-weighted magnetic resonance image.
Figure 3. Magnetic resonance spectroscopy imaging.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
